The diversity of T-cell receptor (TCR) repertoires, as generated by somatic DNA
rearrangements, is central to immune system function. High-throughput sequencing …

Alternatively activated macrophages (M2) can secrete chemokines, such as chemokine
ligand 17 (CCL17), and are associated with promoting tumorigenesis of hepatocellular …

Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell
leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional …

Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive hematological malignancy
derived from mature CD4+ T-lymphocytes. Here, we demonstrate the transcriptional …

IRF4 is a master regulator of immunity and is also frequently overexpressed in mature
lymphoid neoplasms. Here, we demonstrate the oncogenicity of IRF4 in vivo, its potential …

Background/Aim: Adult T-cell leukemia (ATL) is a peripheral T-lymphocytic malignancy
influenced by human T-cell leukemia virus type 1 (HTLV-1) infection. Aggressive ATL has a …

Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute,
lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic …

The prognosis of aggressive adult T-cell leukemia-lymphoma (ATL) remains poor because
of frequent infections and drug resistance. Dose-intensified chemotherapy followed by …

The inhibitory receptor PD-1 is critical to balancing antigen-induced T cell activation; its
inhibition is currently being explored to enhance antitumor T cell immunity with certain …

Background Human T-cell lymphotropic virus type 1 (HTLV-1) and bovine leukemia virus
(BLV) are oncogenic viruses that induce adult T cell leukemia/lymphoma (ATLL) and …